Literature DB >> 18626011

Microsatellites as EWS/FLI response elements in Ewing's sarcoma.

Kunal Gangwal1, Savita Sankar, Peter C Hollenhorst, Michelle Kinsey, Stephen C Haroldsen, Atul A Shah, Kenneth M Boucher, W Scott Watkins, Lynn B Jorde, Barbara J Graves, Stephen L Lessnick.   

Abstract

The ETS gene family is frequently involved in chromosome translocations that cause human cancer, including prostate cancer, leukemia, and sarcoma. However, the mechanisms by which oncogenic ETS proteins, which are DNA-binding transcription factors, target genes necessary for tumorigenesis is not well understood. Ewing's sarcoma serves as a paradigm for the entire class of ETS-associated tumors because nearly all cases harbor recurrent chromosomal translocations involving ETS genes. The most common translocation in Ewing's sarcoma encodes the EWS/FLI oncogenic transcription factor. We used whole genome localization (ChIP-chip) to identify target genes that are directly bound by EWS/FLI. Analysis of the promoters of these genes demonstrated a significant over-representation of highly repetitive GGAA-containing elements (microsatellites). In a parallel approach, we found that EWS/FLI uses GGAA microsatellites to regulate the expression of some of its target genes including NR0B1, a gene required for Ewing's sarcoma oncogenesis. The microsatellite in the NR0B1 promoter bound EWS/FLI in vitro and in vivo and was both necessary and sufficient to confer EWS/FLI regulation to a reporter gene. Genome wide computational studies demonstrated that GGAA microsatellites were enriched close to EWS/FLI-up-regulated genes but not down-regulated genes. Mechanistic studies demonstrated that the ability of EWS/FLI to bind DNA and modulate gene expression through these repetitive elements depended on the number of consecutive GGAA motifs. These findings illustrate an unprecedented route to specificity for ETS proteins and use of microsatellites in tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18626011      PMCID: PMC2481306          DOI: 10.1073/pnas.0801073105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  27 in total

1.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

Authors:  Scott A Tomlins; Daniel R Rhodes; Sven Perner; Saravana M Dhanasekaran; Rohit Mehra; Xiao-Wei Sun; Sooryanarayana Varambally; Xuhong Cao; Joelle Tchinda; Rainer Kuefer; Charles Lee; James E Montie; Rajal B Shah; Kenneth J Pienta; Mark A Rubin; Arul M Chinnaiyan
Journal:  Science       Date:  2005-10-28       Impact factor: 47.728

2.  Centre d'etude du polymorphisme humain (CEPH): collaborative genetic mapping of the human genome.

Authors:  J Dausset; H Cann; D Cohen; M Lathrop; J M Lalouel; R White
Journal:  Genomics       Date:  1990-03       Impact factor: 5.736

3.  Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein.

Authors:  K B Hahm; K Cho; C Lee; Y H Im; J Chang; S G Choi; P H Sorensen; C J Thiele; S J Kim
Journal:  Nat Genet       Date:  1999-10       Impact factor: 38.330

4.  Fitting a mixture model by expectation maximization to discover motifs in biopolymers.

Authors:  T L Bailey; C Elkan
Journal:  Proc Int Conf Intell Syst Mol Biol       Date:  1994

5.  Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation.

Authors:  W A May; M L Gishizky; S L Lessnick; L B Lunsford; B C Lewis; O Delattre; J Zucman; G Thomas; C T Denny
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

6.  Multiple domains mediate transformation by the Ewing's sarcoma EWS/FLI-1 fusion gene.

Authors:  S L Lessnick; B S Braun; C T Denny; W A May
Journal:  Oncogene       Date:  1995-02-02       Impact factor: 9.867

7.  The FLI-1 and chimeric EWS-FLI-1 oncoproteins display similar DNA binding specificities.

Authors:  X Mao; S Miesfeldt; H Yang; J M Leiden; C B Thompson
Journal:  J Biol Chem       Date:  1994-07-08       Impact factor: 5.157

8.  The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1.

Authors:  W A May; S L Lessnick; B S Braun; M Klemsz; B C Lewis; L B Lunsford; R Hromas; C T Denny
Journal:  Mol Cell Biol       Date:  1993-12       Impact factor: 4.272

9.  Loss of tumorigenicity of Ewing's sarcoma cells expressing antisense RNA to EWS-fusion transcripts.

Authors:  M Ouchida; T Ohno; Y Fujimura; V N Rao; E S Reddy
Journal:  Oncogene       Date:  1995-09-21       Impact factor: 9.867

10.  A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature.

Authors:  Jeffrey D Hancock; Stephen L Lessnick
Journal:  Cell Cycle       Date:  2007-10-30       Impact factor: 4.534

View more
  123 in total

Review 1.  Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets.

Authors:  Stephen L Lessnick; Marc Ladanyi
Journal:  Annu Rev Pathol       Date:  2011-09-19       Impact factor: 23.472

2.  EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance.

Authors:  Tyler P Robin; Anna Smith; Erin McKinsey; Lisa Reaves; Paul Jedlicka; Heide L Ford
Journal:  Mol Cancer Res       Date:  2012-06-20       Impact factor: 5.852

3.  Linking germline and somatic variation in Ewing sarcoma.

Authors:  Nicholas C Gomez; Ian J Davis
Journal:  Nat Genet       Date:  2015-09       Impact factor: 38.330

Review 4.  Advances in sarcoma genomics and new therapeutic targets.

Authors:  Barry S Taylor; Jordi Barretina; Robert G Maki; Cristina R Antonescu; Samuel Singer; Marc Ladanyi
Journal:  Nat Rev Cancer       Date:  2011-07-14       Impact factor: 60.716

Review 5.  Molecular mechanisms of ETS transcription factor-mediated tumorigenesis.

Authors:  Adwitiya Kar; Arthur Gutierrez-Hartmann
Journal:  Crit Rev Biochem Mol Biol       Date:  2013-09-25       Impact factor: 8.250

6.  EWS/FLI is a Master Regulator of Metabolic Reprogramming in Ewing Sarcoma.

Authors:  Jason M Tanner; Claire Bensard; Peng Wei; Nathan M Krah; John C Schell; Jamie Gardiner; Joshua Schiffman; Stephen L Lessnick; Jared Rutter
Journal:  Mol Cancer Res       Date:  2017-07-18       Impact factor: 5.852

Review 7.  Advances in the Treatment of Pediatric Bone Sarcomas.

Authors:  Patrick J Grohar; Katherine A Janeway; Luke D Mase; Joshua D Schiffman
Journal:  Am Soc Clin Oncol Educ Book       Date:  2017

8.  A novel role for keratin 17 in coordinating oncogenic transformation and cellular adhesion in Ewing sarcoma.

Authors:  Savita Sankar; Jason M Tanner; Russell Bell; Aashi Chaturvedi; R Lor Randall; Mary C Beckerle; Stephen L Lessnick
Journal:  Mol Cell Biol       Date:  2013-09-16       Impact factor: 4.272

9.  Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus.

Authors:  Matt L Harlow; Nichole Maloney; Joseph Roland; Maria Jose Guillen Navarro; Matthew K Easton; Susan M Kitchen-Goosen; Elissa A Boguslawski; Zachary B Madaj; Ben K Johnson; Megan J Bowman; Maurizio D'Incalci; Mary E Winn; Lisa Turner; Galen Hostetter; Carlos María Galmarini; Pablo M Aviles; Patrick J Grohar
Journal:  Cancer Res       Date:  2016-10-03       Impact factor: 12.701

Review 10.  Children's Oncology Group's 2013 blueprint for research: bone tumors.

Authors:  Richard Gorlick; Katherine Janeway; Stephen Lessnick; R Lor Randall; Neyssa Marina
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.